Optimal Outcomes Competitors

We’re evolving health care so everyone can have the opportunity to live their healthiest life. It’s why we put your unique needs at the heart of everything we do, making it easy and affordable to manage health and well-being. We are delivering the right care how and when it’s needed; providing support to make smarter and healthier choices; and making prescription services easier, while helping you save money along the way. It’s everything health care should be. Together, for better health. Optum is part of UnitedHealth Group (NYSE: UNH).

With almost 30 years of expertise, a best-in-the-business team and unrivaled access to data and analytics, Trinity is a modern partner to companies in the life sciences industry. Trinity combines strategy, insights and analytics to help life science executives with clinical and commercial decision-making. We serve over 300 pharmaceutical, biotech and medical device clients, helping them develop the right drugs and devices for today’s market and optimize them once in market. In 2023, the company worked on 75% of all new drug launches and provides ongoing, in-depth, high value thought leadership that helps shape the industry. With a diverse staff of over 1,300 employees and 14 global offices across the U.S., Europe, Asia, and Latin America, Trinity continues to grow both organically and through acquisitions. These acquisitions included BluePrint Research Group, CBPartners, TGaS Advisors, Bell Canyon and D Cube Analytics, the latter of which dramatically leap-frogged Trinity to the leading provider of go-to-market analytics and AI to biopharma companies. Trinity has also entered into a transformative partnership with Bain & Company that has strategically advanced Trinity’s mission to revolutionize the pharmaceutical commercial model. Ultimately, we know that every decision our clients make impacts a life, and when we help our clients achieve their goals, the world benefits.

Celerion, a leader in early clinical research, delivers Applied Translational Medicine. Celerion applies our expertise and experience to translating information gained in research discoveries, to knowledge of drug action and effect in humans to support early drug development decisions and the clinical pharmacology labeling of new medicines. With over 50 years of experience and 600 global clinic beds (including 24 in-hospital), Celerion conducts and analyzes First-in-Human, clinical proof-of-concept, cardiovascular safety (TQT, robust QT), ADME and NDA-enabling clinical pharmacology studies. Celerion provides expertise on modeling and simulation, study design, medical writing (protocols and reports), clinical data sciences, biostatistics, and PK/PD analysis as well as small and large molecule bioanalytical assays through clinical drug development. Regulatory, drug development and program management complement Celerion’s service offerings. Our operations are strategically located in: Lincoln, Nebraska (Corporate Headquarters) Philadelphia, Pennsylvania Phoenix, Arizona Belfast, Northern Ireland,UK Zurich, Switzerland Vienna, Austria Richmond, Virginia Montreal, Quebec, Canada For more information, visit: www.celerion.com